Healing & Recovery
What Does the Research Actually Show About BPC-157 and Tendon Healing?
The short answer
Every study showing BPC-157 speeds tendon repair was done in rats. Across more than a dozen experiments — mostly from one research group at the University of Zagreb since 2003 — the peptide improved Achilles tendon strength, tendon-to-bone healing, and ligament repair in rodent models. Exactly one verifiable human trial of BPC-157 has ever been registered: a 2015 safety study in 42 healthy volunteers that finished in 2016, is still listed as Unknown status, and never reported a result.
Quick answers
- What is it?
- Whether BPC-157, a peptide sold as a tendon-healing aid, actually speeds tendon repair.
- Why are people interested in it?
- People consider using BPC-157 for tendon injuries and want to know if it works in humans, not just lab animals.
- What has actually been studied?
- More than a dozen rat experiments, mostly from one University of Zagreb lab since 2003, on Achilles tendon, tendon-to-bone, and ligament healing, plus exactly one registered human trial (a 2015-2016 Phase 1 safety study in 42 healthy volunteers).
- How strong is the evidence?
- Animal research only — the rat data is consistent and repeated, but the single human trial never reported results, and no human trial has tested BPC-157 on a tendon.
- What don't we know yet?
- Whether BPC-157 speeds tendon healing in humans at all, what a safe or effective human dose looks like, and whether the rat findings translate across species.
- Where can I read the original research?
- Sources at the bottom of this page: Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth and The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.
The short answer: BPC-157's reputation as a tendon-healing peptide rests almost entirely on rat studies. Since 2003, researchers — mostly a single group at the University of Zagreb — have repeatedly shown that injected BPC-157 speeds tendon, ligament, and tendon-to-bone healing in rodent injury models, sometimes restoring full biomechanical integrity to a severed Achilles tendon within days. Exactly one verifiable human trial has ever been registered — a 2015 safety study that finished a decade ago and never reported. No human trial has tested BPC-157 on a tendon.
What the research shows
The rodent data is real, repeated, and specific
BPC-157 ("Body Protection Compound-157") is a synthetic 15-amino-acid fragment derived from a protein found in human gastric juice. It was originally studied for gastrointestinal ulcers, and its tendon-healing reputation grew out of a parallel line of animal work from the same Croatian lab. In a foundational 2003 study, researchers surgically transected the Achilles tendon of rats and gave daily intraperitoneal injections of BPC-157 at doses as low as 10 picograms per kilogram. Compared to saline-treated controls — which the authors described as showing "severely compromised healing" — BPC-157-treated rats showed higher load to failure, higher Young's modulus of elasticity, better functional scores on a validated gait index, and "reestablishment of full tendon integrity" on macroscopic and microscopic exam, according to PubMed. DOI00110-4)
A related 2006 study went further, testing what happens when a tendon is detached entirely from bone — a tendon-to-bone injury that "could not be healed spontaneously" in untreated rats. BPC-157 restored functional, biomechanical, and histological healing, and specifically counteracted the healing-impairing effect of the corticosteroid methylprednisolone, which the same team showed consistently worsens tendon-to-bone repair on its own. DOI A separate 2010 study extended the pattern to ligaments, showing BPC-157 improved medial collateral ligament healing in rats whether it was given by injection, in drinking water, or as a topical cream. DOI
A proposed mechanism, tested in cells taken from rats
A 2010 mechanistic study tried to explain how BPC-157 might work. Researchers cultured tendon fibroblasts taken from rat Achilles tendons and exposed them to BPC-157 in vitro. The peptide did not directly increase cell proliferation, but it did increase cell migration, spreading, and survival under oxidative stress, and it activated the FAK-paxillin signaling pathway involved in cell adhesion and movement. The authors concluded this likely explains the outgrowth of healthy tendon tissue seen in the whole-animal experiments. DOI This is still bench-level cell biology using rat-derived tissue — it does not establish that the same pathway drives healing in a living human tendon.
Two review papers make the state of the field explicit. A 2019 review from Loughborough University noted that "the majority of studies have been performed on small rodent models and the efficacy of BPC 157 is yet to be confirmed in humans," and flagged that only a handful of research groups worldwide have published in-depth BPC-157 studies over two decades. DOI A 2026 review from the same Zagreb group that generated most of the original data again concluded that "further clinical studies will strengthen" the case for BPC-157 in musculoskeletal injury — a statement that, by definition, means the clinical case is not yet made. DOI
What's actually registered for humans
Searching ClinicalTrials.gov for BPC-157 returns three records, but only one describes a real study:
- NCT02637284 — a Phase 1 safety and pharmacokinetics trial in 42 healthy volunteers in Tijuana, Mexico, testing oral BPC-157 tablets. It ran from 2015 to early 2016. Its status is listed as "Unknown," and it has never posted results.
- NCT07752381 — a completed 2025 trial of "Parlay Recover" peptide gummies containing BPC-157, in 40 physically active adults, measuring inflammation markers (hs-CRP, IL-6) and self-reported soreness and recovery over 8 weeks. It finished in November 2025. No results have been posted, and it did not measure tendon structure or strength.
- NCT07437547 — presented as a Phase 2 hamstring-strain trial. This record is not a real study. It belongs to a cluster of three template records sharing one sponsor (Hudson Biotech), one site, one investigator contact, and an identical primary-completion date of 14 February 2027. A sibling record in the same cluster states in its own summary that it is a fictional example. It should not be counted as research activity.
No human trial has ever tested BPC-157 on a torn or degenerated tendon.
What we don't know yet
Whether BPC-157 speeds tendon healing in humans at all. No completed human trial has measured tendon structure, strength, or repair outcomes after BPC-157 treatment.
What a safe or effective human dose looks like. The one trial designed to answer this — a 2015-2016 Phase 1 pharmacokinetics study — never reported its findings.
Whether the rat findings translate across species. All positive tendon results come from a small number of rodent studies, largely from one lab, using injected or orally dosed BPC-157 in surgically standardized injuries very different from how tendon injuries present clinically in people.
Whether oral, subcutaneous, or injectable forms behave the same way. Most positive animal data used intraperitoneal injection; the compound's stability and activity by other routes in humans has not been established in published trial results.
Long-term safety with repeated use. Rodent studies used short courses of days to weeks. No human trial has reported safety data over months or years of use.
Sources
- Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research, 2003;21(6):976-983. DOI00110-4)
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 2010;110(3):774-780. DOI
- Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research, 2006;24(5):982-989. DOI
- Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research, 2010;28(9):1155-1161. DOI
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019;377(2):153-159. DOI
- Matek D, Matek I, Japjec M, et al. Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157 - A Review. Pharmaceuticals, 2026;19(2). DOI
- ClinicalTrials.gov. NCT02637284 (verified). NCT07752381 (a commercial peptide-gummy product, composition not specified). NCT07437547 (template record — not a real study; see correction). Retrieved August 2026.
Article records maintained via PubMed. Peptide Proof reports what studies found. It does not provide medical advice, dosing guidance, or treatment recommendations.
Topic: Recovery & Tissue Research | Evidence Index: bpc-157
Sources
- Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth
- Journal of Orthopaedic Research, 2003 · DOI
- The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
- Journal of Applied Physiology, 2010 · DOI
- Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation
- Journal of Orthopaedic Research, 2006 · DOI
- Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat
- Journal of Orthopaedic Research, 2010 · DOI
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing
- Cell and Tissue Research, 2019 · DOI
- Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157
- Pharmaceuticals, 2026 · DOI
Get the evidence, not the hype.
New research briefs, plainly written and fully sourced. No dosing advice, ever.